WPWS
MCID: WLF001
MIFTS: 66

Wolff-Parkinson-White Syndrome (WPWS)

Categories: Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Wolff-Parkinson-White Syndrome

MalaCards integrated aliases for Wolff-Parkinson-White Syndrome:

Name: Wolff-Parkinson-White Syndrome 56 12 74 52 25 73 29 13 54 6 43 15 17 71
Wolff-Parkinson-White Pattern 12 29 6 39
Wpw Syndrome 56 52 25
Ventricular Familial Preexcitation Syndrome 52 73
Anomalous Atrioventricular Excitation 12 71
Preexcitation Syndrome 52 71
Auriculoventricular Accessory Pathway Syndrome 52
Ventricular Pre-Excitation with Arrhythmia 25
Anomalous Ventricular Excitation Syndrome 52
False Bundle Branch Block Syndrome 52
Wolff-Parkinson-White Syndrome 36
Ventricular Preexcitation 71
Anomalous a-V Excitation 12
Wpws 73

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
onset as early as childhood


HPO:

31
wolff-parkinson-white syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:384
OMIM 56 194200
KEGG 36 H01154
ICD9CM 34 426.7
MeSH 43 D014927
NCIt 49 C35132
SNOMED-CT 67 17869006 74390002
ICD10 32 I45.6
UMLS 71 C0032915 C0043202 C0392470 more

Summaries for Wolff-Parkinson-White Syndrome

Genetics Home Reference : 25 Wolff-Parkinson-White syndrome is a condition characterized by abnormal electrical pathways in the heart that cause a disruption of the heart's normal rhythm (arrhythmia). The heartbeat is controlled by electrical signals that move through the heart in a highly coordinated way. A specialized cluster of cells called the atrioventricular node conducts electrical impulses from the heart's upper chambers (the atria) to the lower chambers (the ventricles). Impulses move through the atrioventricular node during each heartbeat, stimulating the ventricles to contract slightly later than the atria. People with Wolff-Parkinson-White syndrome are born with an extra connection in the heart, called an accessory pathway, that allows electrical signals to bypass the atrioventricular node and move from the atria to the ventricles faster than usual. The accessory pathway may also transmit electrical impulses abnormally from the ventricles back to the atria. This extra connection can disrupt the coordinated movement of electrical signals through the heart, leading to an abnormally fast heartbeat (tachycardia) and other changes in heart rhythm. Resulting symptoms include dizziness, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, and fainting (syncope). In rare cases, arrhythmias associated with Wolff-Parkinson-White syndrome can lead to cardiac arrest and sudden death. The most common arrhythmia associated with Wolff-Parkinson-White syndrome is called paroxysmal supraventricular tachycardia. Complications of Wolff-Parkinson-White syndrome can occur at any age, although some individuals born with an accessory pathway in the heart never experience any health problems associated with the condition. Wolff-Parkinson-White syndrome often occurs with other structural abnormalities of the heart or underlying heart disease. The most common heart defect associated with the condition is Ebstein anomaly, which affects the valve that allows blood to flow from the right atrium to the right ventricle (the tricuspid valve). Additionally, the heart rhythm problems associated with Wolff-Parkinson-White syndrome can be a component of several other genetic syndromes, including hypokalemic periodic paralysis (a condition that causes episodes of extreme muscle weakness), Pompe disease (a disorder characterized by the storage of excess glycogen), Danon disease (a condition that weakens the heart and skeletal muscles and causes intellectual disability), and tuberous sclerosis complex (a condition that results in the growth of noncancerous tumors in many parts of the body).

MalaCards based summary : Wolff-Parkinson-White Syndrome, also known as wolff-parkinson-white pattern, is related to danon disease and ventricular fibrillation, paroxysmal familial, 1. An important gene associated with Wolff-Parkinson-White Syndrome is PRKAG2 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2), and among its related pathways/superpathways are Insulin signaling pathway and Adipocytokine signaling pathway. The drugs Angiotensin II and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and atrioventricular node, and related phenotypes are sudden cardiac death and stroke

NIH Rare Diseases : 52 Wolff-Parkinson-White syndrome causes a problem with the rate or rhythm of the heartbeat (arrhythmia ). People with the syndrome are born with a heart abnormality that affects the coordinated movement of electrical signals through the heart. This leads to an abnormally fast heartbeat (tachycardia ) and other arrhythmias. The most common arrhythmia associated with Wolff-Parkinson-White syndrome is paroxysmal supraventricular tachycardia . The syndrome is especially common in people of Chinese descent. In most cases, the cause of Wolff-Parkinson-White syndrome is unknown. A small percentage of cases are caused by genetic changes (mutations or pathogenic variants) in the PRKAG2 gene . These cases appear to be inherited in an autosomal dominant manner. A diagnosis of the syndrome is based on an electrocardiogram (ECG) or Holter test that shows episodes of tachycardia. Treatment for the syndrome may depend on the severity of symptoms but can include medications or surgery.

KEGG : 36 Wolff-Parkinson-White (WPW) syndrome is the most common cause of ventricular pre-excitation, a condition where all or part of the ventricle is excited earlier than would normally be expected, often leading to ventricular fibrillation and sudden cardiac death. It was recently discovered that mutations in PRKAG2, that encodes a subunit of the AMP-activated protein kinase, is responsible for WPW syndrome.

UniProtKB/Swiss-Prot : 73 Wolff-Parkinson-White syndrome: A supernormal conduction disorder characterized by the presence of one or several accessory atrioventricular connections, which can lead to episodes of sporadic tachycardia.

Wikipedia : 74 Wolff-Parkinson-White syndrome (WPWS) is a disorder due to a specific type of problem with the... more...

More information from OMIM: 194200

Related Diseases for Wolff-Parkinson-White Syndrome

Diseases related to Wolff-Parkinson-White Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 danon disease 33.8 PRKAG2 MYH7 MYBPC3
2 ventricular fibrillation, paroxysmal familial, 1 32.7 TNNT2 NKX2-5 KCNQ1
3 atrial fibrillation 32.5 TNNT2 TNNI3 NPPB MYH7 MYBPC3 KCNQ1
4 cardiac conduction defect 32.4 MYH7 MYBPC3 KCNQ1
5 atrioventricular block 32.2 TNNI3 NPPB NKX2-5 MYH7 KCNQ1
6 left bundle branch hemiblock 32.2 TNNT2 TNNT1 TNNI3 NPPB
7 atrial standstill 1 32.1 TNNT2 TNNI3 PRKAG2 NPPB MYH7 MYBPC3
8 heart septal defect 32.1 TNNT2 TBX20 NKX2-5 JAG1
9 cardiac arrest 32.0 TNNT2 NPPB MYH7 MYBPC3 KCNQ1 CASQ2
10 inferior myocardial infarction 31.7 TNNI3 NPPB
11 atrial heart septal defect 31.7 TNNT2 TNNI3 TBX20 NPPB NKX2-5 MYH7
12 mitral valve insufficiency 31.7 TNNT2 TNNI3 NPPB MYBPC3
13 pericarditis 31.6 TNNT2 TNNI3 NPPB
14 congestive heart failure 31.6 TNNT2 TNNI3 NPPB MYH7 MYBPC3 KCNQ1
15 ventricular septal defect 31.6 NPPB NKX2-5 MYH7 JAG1
16 cardiomyopathy, familial hypertrophic, 1 31.6 TNNT2 MYH7 MYBPC3 KCNQ1
17 hypertrophic cardiomyopathy 31.5 TNNT2 TNNT1 TNNI3 PRKAG2 PRKAA2 NPPB
18 brugada syndrome 31.5 TNNT2 TNNI3 PRKAG2 NKX2-5 MYH7 MYBPC3
19 patent ductus arteriosus 1 31.4 TBX20 NPPB NKX2-5 JAG1
20 dilated cardiomyopathy 31.4 TNNT2 TNNT1 TNNI3 TBX20 PRKAG2 NPPB
21 congenitally corrected transposition of the great arteries 31.3 TNNT2 NPPB
22 patent foramen ovale 31.3 TNNT2 TNNI3 TBX20 NPPB NKX2-5
23 heart valve disease 31.2 TNNI3 NPPB NKX2-5
24 intermediate coronary syndrome 31.2 TNNT2 TNNT1 TNNI3
25 heart disease 31.2 TNNT2 TNNI3 TBX20 NPPB NKX2-5 MYH7
26 pulmonary embolism 31.2 TNNT2 TNNT1 TNNI3 NPPB
27 tricuspid valve disease 31.2 TNNI3 NPPB NKX2-5 MYH7
28 noonan syndrome with multiple lentigines 31.1 TNNT2 NKX2-5 MYH7 MYBPC3 KCNQ1
29 familial atrial fibrillation 31.0 NKX2-5 MYH7 MYBPC3 KCNQ1 CASQ2
30 tetralogy of fallot 30.9 TNNT2 TNNI3 TBX20 NPPB NKX2-5 JAG1
31 rheumatic myocarditis 30.9 TNNT2 TNNI3
32 first-degree atrioventricular block 30.6 NPPB MYH7
33 cardiomyopathy, familial hypertrophic, 6 12.2
34 cardiomyopathy, infantile histiocytoid 11.9
35 20p12.3 microdeletion syndrome 11.8
36 myoclonic epilepsy associated with ragged-red fibers 11.3
37 syncope 11.1
38 progressive familial heart block, type ia 11.1
39 progressive familial heart block, type ib 10.9
40 right bundle branch block 10.9
41 myocardial infarction 10.9
42 mitral valve stenosis 10.8
43 orthostatic intolerance 10.7
44 tuberous sclerosis 10.7
45 cardiac tamponade 10.7
46 familial isolated restrictive cardiomyopathy 10.6 TNNT2 TNNI3
47 pallister w syndrome 10.6
48 tricuspid atresia 10.6
49 sick sinus syndrome 10.6
50 glycogen storage disease of heart, lethal congenital 10.6 PRKAG2-AS1 PRKAG2

Comorbidity relations with Wolff-Parkinson-White Syndrome via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Intermediate Coronary Syndrome Mitral Valve Disease

Graphical network of the top 20 diseases related to Wolff-Parkinson-White Syndrome:



Diseases related to Wolff-Parkinson-White Syndrome

Symptoms & Phenotypes for Wolff-Parkinson-White Syndrome

Human phenotypes related to Wolff-Parkinson-White Syndrome:

31 (show all 10)
# Description HPO Frequency HPO Source Accession
1 sudden cardiac death 31 HP:0001645
2 stroke 31 HP:0001297
3 cardiomyopathy 31 HP:0001638
4 paroxysmal atrial fibrillation 31 HP:0004757
5 wolff-parkinson-white syndrome 31 HP:0001716
6 palpitations 31 HP:0001962
7 shortened pr interval 31 HP:0005165
8 prolonged qrs complex 31 HP:0006677
9 paroxysmal supraventricular tachycardia 31 HP:0004763
10 ventricular preexcitation with multiple accessory pathways 31 HP:0006684

Symptoms via clinical synopsis from OMIM:

56
Cardiovascular Heart:
paroxysmal atrial fibrillation
ventricular preexcitation
paroxysmal supraventricular tachycardia
short pr interval (<120 msec)
widened qrs complex (>110 msec)
more
Cardiovascular Vascular:
hypertension (in some patients)

Clinical features from OMIM:

194200

MGI Mouse Phenotypes related to Wolff-Parkinson-White Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.93 BMP2 CASQ2 DNAAF3 JAG1 KCNQ1 MYBPC3
2 homeostasis/metabolism MP:0005376 9.8 BMP2 CASQ2 JAG1 KCNQ1 MYBPC3 MYH7
3 muscle MP:0005369 9.47 CASQ2 JAG1 KCNQ1 MYBPC3 MYH7 NKX2-5

Drugs & Therapeutics for Wolff-Parkinson-White Syndrome

Drugs for Wolff-Parkinson-White Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
5 Antihypertensive Agents Phase 4
6 Adrenergic Agents Phase 4
7 Vasodilator Agents Phase 4
8 Neurotransmitter Agents Phase 4
9 Adrenergic beta-Agonists Phase 4
10 Angiotensin II Type 1 Receptor Blockers Phase 4
11 Angiotensinogen Phase 4
12 Angiotensin Receptor Antagonists Phase 4
13 Giapreza Phase 4
14 Adrenergic Agonists Phase 4
15
Digoxin Approved Phase 3 20830-75-5 30322 2724385
16
Propranolol Approved, Investigational Phase 3 525-66-6 4946
17 Adrenergic beta-Antagonists Phase 3
18 Cardiotonic Agents Phase 3
19 Adrenergic Antagonists Phase 3
20 Anti-Arrhythmia Agents Phase 3
21 Protective Agents Phase 3
22
Verapamil Approved Phase 2 52-53-9 2520
23
Hydroxyurea Approved Phase 2 127-07-1 3657
24 Hormones Phase 2
25 Calcium, Dietary Phase 2
26 calcium channel blockers Phase 2
27 Anti-Retroviral Agents Phase 2
28
Calcium Nutraceutical Phase 2 7440-70-2 271
29
Procainamide Approved 51-06-9 4913
30
Amiodarone Approved, Investigational 1951-25-3 2157
31
Adenosine Approved, Investigational 58-61-7 60961
32 Sodium Channel Blockers
33 Cytochrome P-450 Enzyme Inhibitors
34 Potassium Channel Blockers
35 Diuretics, Potassium Sparing
36 Analgesics
37 Cytochrome P-450 CYP3A Inhibitors

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
2 Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia Completed NCT00390546 Phase 3 Digoxin;Propranolol
3 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
4 Management of Supraventricular Tachycardia of Children Admitted to Assiut University Children Hospital(Clinical Audit) Unknown status NCT03528616 adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.
5 Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases Unknown status NCT00221832
6 Mini-invasive Electrophysiology Study as a Routine Examination for Patients Complaining of Tachycardia, But With a Negative Holter ECG. Completed NCT00251121
7 A Comparative Study of Different Treadmill Scores to Diagnose Coronary Artery Disease Among Patients Attending Bangabandhu Sheikh Mujib Medical University Completed NCT02879032
8 A Single Center Prospective, Pilot Study Examining the Non-invasive Evaluation of Ventricular Synchrony in Pediatric Patients Completed NCT00165932
9 Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope Completed NCT01814228
10 Safety and Efficacy of Cryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory Pathways: a Randomized Comparative Trial Recruiting NCT04361006
11 Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation Recruiting NCT03301935
12 Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias: a Randomized Controlled Trial Recruiting NCT04078685
13 Reproducibility and Validity of the Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With Preexcitation (WPW Pattern) Enrolling by invitation NCT03207373
14 Accessory Pathway Antegrade Effective Refractory Period Among Wolff Parkinson White Patients: the Risk in Relation to the Location Not yet recruiting NCT04106622
15 The Efficacy and Safety of Left Atrial Appendage Closure in Combination With Catheter Ablation in Patients With Atrial Fibrillation Not yet recruiting NCT03788941
16 Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Not yet recruiting NCT04027270
17 Long Term Evolution of the Anterograde Refractory Period of Accessory Duct in the Wolff-Parkinson-White Syndrome Terminated NCT00873470
18 Comparison of the Acute Hemodynamic Effect of Three Modes of Stimulation in Cardiac Resynchronization. Terminated NCT03779802

Search NIH Clinical Center for Wolff-Parkinson-White Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Adenosine
Adenosine Monophosphate
ADENOSINE MONOPHOSPHATE PWDR
ADENOSINE PHOSPHATE SODIUM
Adenosine Triphosphate

Cochrane evidence based reviews: wolff-parkinson-white syndrome

Genetic Tests for Wolff-Parkinson-White Syndrome

Genetic tests related to Wolff-Parkinson-White Syndrome:

# Genetic test Affiliating Genes
1 Wolff-Parkinson-White Pattern 29 PRKAG2
2 Wolff-Parkinson-White Syndrome 29

Anatomical Context for Wolff-Parkinson-White Syndrome

MalaCards organs/tissues related to Wolff-Parkinson-White Syndrome:

40
Heart, Testes, Atrioventricular Node, Skeletal Muscle, Prostate, Brain, Thyroid

Publications for Wolff-Parkinson-White Syndrome

Articles related to Wolff-Parkinson-White Syndrome:

(show top 50) (show all 3517)
# Title Authors PMID Year
1
A gene responsible for familial Wolff-Parkinson-White syndrome. 61 6 56
11586962 2001
2
Electrophysiologic characteristics of accessory atrioventricular connections in an inherited form of Wolff-Parkinson-White syndrome. 6 56 61
10355918 1999
3
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. 54 61 6
11827995 2002
4
Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. 56 61 54
11748095 2001
5
Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. 61 56
15371577 2004
6
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. 61 56
11407343 2001
7
Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. 61 56
7657794 1995
8
Familial Wolff-Parkinson-White syndrome. 61 56
7069337 1982
9
A proposed autosomal dominant method of inheritance of the Wolff-Parkinson-White syndrome and supraventricular tachycardia. 61 56
671163 1978
10
Familial occurrence of Wolff-Parkinson-White syndrome. 61 56
5794793 1969
11
Familial Wolff-Parkinson-White syndrome with cardiomyopathy. 56 61
4228766 1967
12
Hereditary occurrence of the pre-excitation (Wolff-Parkinson-White) syndrome with re-entry mechanism and concealed conduction. 61 56
13619017 1959
13
Genetically transmitted ventricular pre-excitation in a family with hypertrophic cardiomyopathy. 6
10820940 2000
14
Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. 56
9241277 1997
15
Clinical manifestations and prevalence of different types of supraventricular tachycardia among Chinese. 56
1618009 1992
16
Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). 56
3587328 1987
17
A 17-year follow-up study of a family with idiopathic hypertrophic cardiomyopathy and WPW syndrome. 56
567705 1978
18
20p12.3 microdeletion predisposes to Wolff-Parkinson-White syndrome with variable neurocognitive deficits. 54 61
18812404 2009
19
[AMP-activated protein kinase: how a mistake in energy gauge causes glycogen storage]. 54 61
17990392 2007
20
[A familial form of conduction defects associated with a PRKAG2 gene mutation]. 54 61
18033003 2007
21
Role of AMP-activated protein kinase in healthy and diseased hearts. 54 61
16844922 2006
22
Familial pseudo-Wolff-Parkinson-White syndrome. 54 61
16836667 2006
23
Familial Wolff-Parkinson-White Syndrome: a disease of glycogen storage or ion channel dysfunction? 54 61
16686673 2006
24
Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. 61 54
15877279 2005
25
Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. 61 54
15611370 2005
26
Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathies: implications for kinase function and disease pathogenesis. 54 61
14519435 2003
27
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. 54 61
12782567 2003
28
Molecular genetic analysis of PRKAG2 in sporadic Wolff-Parkinson-White syndrome. 61 54
12716108 2003
29
Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. 61 54
12397075 2002
30
Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. 61 54
11371514 2001
31
Histological examination of the potential arrhythmic substrates in the setting of Ebstein's malformation. 61
32115720 2020
32
The Case of Flecainide Toxicity: What to Look for and How to Treat. 61
32536493 2020
33
An unusual treatment of coronary injury following radiofrequency ablation in a 5-year-old child: systemic steroid usage. 61
32543718 2020
34
The heart in m.3243A>G carriers. 61
30128910 2020
35
Novel Assessment of Accessory Pathway Function in Patients with Wolff-Parkinson-White Syndrome. 61
32529357 2020
36
Wolff-Parkinson-White syndrome: De novo variants and evidence for mutational burden in genes associated with atrial fibrillation. 61
32233023 2020
37
Clinical characteristics of challenging catheter ablation procedures in patients with WPW syndrome: A 10 year single-center experience. 61
32532584 2020
38
Loss of Ventricular Pre-excitation During Non-invasive Testing Does Not Exclude High-Risk Accessory Pathways: A Multicenter Study of WPW in Children. 61
32497761 2020
39
Lipomatous hypertrophy of the interventricular septum. 61
32484973 2020
40
Intra-cardiac ultrasound guided approach for catheter ablation of typical right free wall accessory pathways. 61
32375635 2020
41
Increased pre-excitation in ECG improves accuracy of algorithms for accessory pathway localization in Wolff-Parkinson-White syndrome. 61
32438794 2020
42
Evolution of acute ST-segment elevation myocardial infarction in a patient with ventricular preexcitation. 61
32413694 2020
43
Indices of left ventricular voltage on electrocardiogram are closely associated with serum cardiac troponin I levels in normotensive Japanese individuals. 61
32384453 2020
44
Adult onset tubulo-interstitial nephropathy in MT-ND5-related phenotypes. 61
31713837 2020
45
Inappropriate Shock from Subcutaneous Implantable Cardioverter-Defibrillator Caused by Electrical Remodeling After Wolff-Parkinson-White Ablation. 61
32461842 2020
46
Diagnostic yield of hypertrophic cardiomyopathy in first-degree relatives of decedents with idiopathic left ventricular hypertrophy. 61
32011662 2020
47
Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias (COBRA-PATH): a randomized controlled trial. 61
32272969 2020
48
Ischaemia during exercise stress testing in an athlete with Wolff-Parkinson-White pattern. 61
32300041 2020
49
Success rate and safety of catheter ablation in preexcitation syndrome: A comparison between adult and pediatric patients. 61
32207846 2020
50
Early repolarization in the inferior leads after accessory pathway ablation is highly correlated with atrial fibrillation in Wolff-Parkinson-White syndrome. 61
31445855 2020

Variations for Wolff-Parkinson-White Syndrome

ClinVar genetic disease variations for Wolff-Parkinson-White Syndrome:

6 (show top 50) (show all 195) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PRKAG2 NM_016203.4(PRKAG2):c.547G>A (p.Glu183Lys)SNV Pathogenic 430968 rs1131692281 7:151372643-151372643 7:151675557-151675557
2 TBX20 NM_001077653.2(TBX20):c.995del (p.Pro332fs)deletion Pathogenic 438266 rs1554284604 7:35244090-35244090 7:35204478-35204478
3 SLC26A4 NM_000441.2(SLC26A4):c.85G>C (p.Glu29Gln)SNV Pathogenic 4839 rs111033205 7:107302171-107302171 7:107661726-107661726
4 PRKAG2 NM_016203.4(PRKAG2):c.905G>A (p.Arg302Gln)SNV Pathogenic 6846 rs121908987 7:151273498-151273498 7:151576412-151576412
5 KCNQ1 NM_181798.1(KCNQ1):c.343G>A (p.Asp115Asn)SNV Pathogenic 53090 rs199472712 11:2593283-2593283 11:2572053-2572053
6 MYH7 NM_000257.4(MYH7):c.2389G>A (p.Ala797Thr)SNV Pathogenic/Likely pathogenic 42901 rs3218716 14:23894525-23894525 14:23425316-23425316
7 TNNT2 NM_001276345.2(TNNT2):c.360T>G (p.Phe120Leu)SNV Pathogenic/Likely pathogenic 177807 rs727504331 1:201334370-201334370 1:201365242-201365242
8 ABCC9 NM_005691.3(ABCC9):c.2019+2T>CSNV Likely pathogenic 487597 rs1555100687 12:22035698-22035698 12:21882764-21882764
9 ACTC1 NM_005159.5(ACTC1):c.524_525insC (p.Ala176fs)insertion Likely pathogenic 487625 rs1555418832 15:35084700-35084701 15:34792499-34792500
10 CASQ2 NM_001232.3(CASQ2):c.2T>C (p.Met1Thr)SNV Likely pathogenic 452250 rs1553197939 1:116311161-116311161 1:115768540-115768540
11 TNNT2 NM_001276345.2(TNNT2):c.3G>A (p.Met1Ile)SNV Likely pathogenic 487631 rs1289914935 1:201342380-201342380 1:201373252-201373252
12 TTN NM_001267550.2(TTN):c.66904C>T (p.Leu22302=)SNV Likely pathogenic 487595 rs1553624186 2:179445202-179445202 2:178580475-178580475
13 TTN NM_001267550.2(TTN):c.92683C>T (p.Arg30895Ter)SNV Likely pathogenic 223300 rs869312065 2:179413670-179413670 2:178548943-178548943
14 PRKAG2 NM_016203.4(PRKAG2):c.981A>G (p.Leu327=)SNV Conflicting interpretations of pathogenicity 227880 rs764162597 7:151272001-151272001 7:151574915-151574915
15 PRKAG2 NM_016203.4(PRKAG2):c.429G>A (p.Ser143=)SNV Conflicting interpretations of pathogenicity 359346 rs757727533 7:151478275-151478275 7:151781189-151781189
16 PRKAG2 NM_016203.4(PRKAG2):c.248C>T (p.Pro83Leu)SNV Conflicting interpretations of pathogenicity 359348 rs757900380 7:151478456-151478456 7:151781370-151781370
17 PRKAG2 NM_016203.4(PRKAG2):c.138G>A (p.Pro46=)SNV Conflicting interpretations of pathogenicity 359351 rs767613486 7:151483604-151483604 7:151786518-151786518
18 PRKAG2 NM_016203.4(PRKAG2):c.*135T>CSNV Conflicting interpretations of pathogenicity 359340 rs184932311 7:151254152-151254152 7:151557066-151557066
19 PRKAG2 NM_016203.4(PRKAG2):c.*572G>ASNV Conflicting interpretations of pathogenicity 359334 rs78192883 7:151253715-151253715 7:151556629-151556629
20 PRKAG2 NM_016203.3(PRKAG2):c.-520C>TSNV Conflicting interpretations of pathogenicity 359364 rs73160072 7:151574225-151574225 7:151877140-151877140
21 PRKAG2 NM_016203.4(PRKAG2):c.-16A>GSNV Conflicting interpretations of pathogenicity 359352 rs200468798 7:151573721-151573721 7:151876636-151876636
22 PRKAG2 NM_016203.4(PRKAG2):c.-287C>GSNV Conflicting interpretations of pathogenicity 359359 rs75059373 7:151573992-151573992 7:151876907-151876907
23 PRKAG2 NM_016203.4(PRKAG2):c.750C>T (p.Asp250=)SNV Conflicting interpretations of pathogenicity 378428 rs201735117 7:151329159-151329159 7:151632073-151632073
24 PRKAG2 NM_016203.4(PRKAG2):c.88A>C (p.Arg30=)SNV Conflicting interpretations of pathogenicity 465343 rs756923555 7:151573618-151573618 7:151876533-151876533
25 PRKAG2 NM_016203.4(PRKAG2):c.432C>T (p.Pro144=)SNV Conflicting interpretations of pathogenicity 520278 rs764742900 7:151478272-151478272 7:151781186-151781186
26 NODAL NM_018055.5(NODAL):c.778G>A (p.Gly260Arg)SNV Conflicting interpretations of pathogenicity 8269 rs121909283 10:72195155-72195155 10:70435399-70435399
27 MYH7 NM_000257.4(MYH7):c.728G>A (p.Arg243His)SNV Conflicting interpretations of pathogenicity 14126 rs267606910 14:23900798-23900798 14:23431589-23431589
28 MYH6 NM_002471.4(MYH6):c.3010G>T (p.Ala1004Ser)SNV Conflicting interpretations of pathogenicity 14151 rs143978652 14:23862646-23862646 14:23393437-23393437
29 PRKAG2 NM_016203.4(PRKAG2):c.912G>A (p.Ala304=)SNV Conflicting interpretations of pathogenicity 45738 rs145029525 7:151273491-151273491 7:151576405-151576405
30 MYBPC3 NM_000256.3(MYBPC3):c.1321G>A (p.Glu441Lys)SNV Conflicting interpretations of pathogenicity 36601 rs193922377 11:47364602-47364602 11:47343051-47343051
31 PRKAG2 NM_016203.4(PRKAG2):c.1593G>A (p.Arg531=)SNV Conflicting interpretations of pathogenicity 36696 rs148197254 7:151257695-151257695 7:151560609-151560609
32 PRKAG2 NM_016203.4(PRKAG2):c.298G>A (p.Gly100Ser)SNV Conflicting interpretations of pathogenicity 36697 rs79474211 7:151478406-151478406 7:151781320-151781320
33 MYBPC3 NM_000256.3(MYBPC3):c.1591G>C (p.Gly531Arg)SNV Conflicting interpretations of pathogenicity 42550 rs397515912 11:47364162-47364162 11:47342611-47342611
34 PRKAG2 NM_016203.4(PRKAG2):c.*2C>TSNV Conflicting interpretations of pathogenicity 177987 rs199559205 7:151254285-151254285 7:151557199-151557199
35 PRKAG2 NM_016203.4(PRKAG2):c.698C>G (p.Ala233Gly)SNV Conflicting interpretations of pathogenicity 45733 rs201240745 7:151329211-151329211 7:151632125-151632125
36 KCNQ1 NM_181798.1(KCNQ1):c.808C>T (p.Arg270Trp)SNV Conflicting interpretations of pathogenicity 52970 rs199472776 11:2608860-2608860 11:2587630-2587630
37 PRKAG2 NM_016203.4(PRKAG2):c.202G>A (p.Gly68Ser)SNV Conflicting interpretations of pathogenicity 181465 rs730880970 7:151478502-151478502 7:151781416-151781416
38 CACNA1C NM_000719.7(CACNA1C):c.2579G>A (p.Arg860Gln)SNV Conflicting interpretations of pathogenicity 190654 rs730880056 12:2702427-2702427 12:2593261-2593261
39 SNTA1 NM_003098.2(SNTA1):c.1088A>C (p.Glu363Ala)SNV Conflicting interpretations of pathogenicity 190918 rs147964932 20:31998090-31998090 20:33410284-33410284
40 LAMA4 NM_001105206.3(LAMA4):c.2398C>T (p.Arg800Cys)SNV Conflicting interpretations of pathogenicity 192119 rs202184174 6:112466091-112466091 6:112144889-112144889
41 PRKAG2 NM_016203.4(PRKAG2):c.186+7C>TSNV Conflicting interpretations of pathogenicity 359350 rs886062102 7:151483549-151483549 7:151786463-151786463
42 PRKAG2 NM_016203.4(PRKAG2):c.947-7G>ASNV Conflicting interpretations of pathogenicity 465344 rs1554464198 7:151272042-151272042 7:151574956-151574956
43 PRKAG2 NM_016203.4(PRKAG2):c.1098A>G (p.Pro366=)SNV Conflicting interpretations of pathogenicity 45686 rs116541276 7:151267265-151267265 7:151570179-151570179
44 PRKAG2 NM_016203.4(PRKAG2):c.1106+9G>CSNV Conflicting interpretations of pathogenicity 45687 rs200429988 7:151267248-151267248 7:151570162-151570162
45 PRKAG2 NM_016203.4(PRKAG2):c.111T>A (p.Ile37=)SNV Conflicting interpretations of pathogenicity 45688 rs144426409 7:151573595-151573595 7:151876510-151876510
46 RYR2 NM_001035.3(RYR2):c.8162T>C (p.Ile2721Thr)SNV Conflicting interpretations of pathogenicity 43828 rs201500134 1:237821276-237821276 1:237657976-237657976
47 PRKAG2 NM_016203.4(PRKAG2):c.123C>T (p.Ser41=)SNV Conflicting interpretations of pathogenicity 45692 rs397517263 7:151483619-151483619 7:151786533-151786533
48 KCNQ1 NM_000218.3(KCNQ1):c.1621G>A (p.Val541Ile)SNV Conflicting interpretations of pathogenicity 67043 rs199472796 11:2797220-2797220 11:2775990-2775990
49 SCN5A NM_198056.2(SCN5A):c.1567C>T (p.Arg523Cys)SNV Conflicting interpretations of pathogenicity 67667 rs199473119 3:38645526-38645526 3:38604035-38604035
50 PRKAG2 NM_016203.4(PRKAG2):c.471C>T (p.Ser157=)SNV Conflicting interpretations of pathogenicity 45721 rs141804012 7:151372719-151372719 7:151675633-151675633

UniProtKB/Swiss-Prot genetic disease variations for Wolff-Parkinson-White Syndrome:

73
# Symbol AA change Variation ID SNP ID
1 PRKAG2 p.Arg302Gln VAR_013264 rs121908987
2 PRKAG2 p.Arg531Gly VAR_032909 rs121908990

Expression for Wolff-Parkinson-White Syndrome

Search GEO for disease gene expression data for Wolff-Parkinson-White Syndrome.

Pathways for Wolff-Parkinson-White Syndrome

Pathways related to Wolff-Parkinson-White Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Insulin signaling pathway hsa04910
2 Adipocytokine signaling pathway hsa04920
3 Hypertrophic cardiomyopathy (HCM) hsa05410

Pathways related to Wolff-Parkinson-White Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 TNNT2 TNNT1 TNNI3 NKX2-5 MYBPC3 KCNQ1
2
Show member pathways
12.49 TNNT2 TNNI3 NPPB MYH7 KCNQ1
3 12.45 PRKAG3 PRKAG2 PRKAA2 PRKAA1
4
Show member pathways
12.44 PRKAG3 PRKAG2 PRKAA2 PRKAA1 NPPB
5
Show member pathways
12.43 PRKAG3 PRKAG2 PRKAA2 PRKAA1
6
Show member pathways
12.41 PRKAG3 PRKAG2 PRKAA2 PRKAA1
7
Show member pathways
12.39 NPPB NKX2-5 MYH7 BMP2
8
Show member pathways
12.34 PRKAG3 PRKAG2 PRKAA2 PRKAA1
9
Show member pathways
12.16 PRKAG3 PRKAG2 PRKAA2 PRKAA1
10 12.13 PRKAG3 PRKAG2 PRKAA2 PRKAA1
11
Show member pathways
12.12 PRKAG3 PRKAG2 PRKAA2 PRKAA1
12
Show member pathways
12.09 PRKAG3 PRKAG2 PRKAA2 PRKAA1
13
Show member pathways
12.04 PRKAG3 PRKAG2 PRKAA2 PRKAA1
14
Show member pathways
11.91 PRKAG3 PRKAG2 PRKAA2 PRKAA1
15 11.88 PRKAG3 PRKAG2 PRKAA2 PRKAA1
16 11.86 PRKAG3 PRKAG2 PRKAA2 PRKAA1 JAG1
17
Show member pathways
11.84 PRKAG3 PRKAG2 PRKAA2 PRKAA1
18 11.82 TNNT2 TNNI3 NKX2-5 BMP2
19 11.76 TNNT2 TNNI3 MYH7 CASQ2
20 11.74 PRKAG3 PRKAG2 PRKAA2 PRKAA1
21 11.66 PRKAG3 PRKAG2 PRKAA2 PRKAA1
22 11.64 TNNT2 TNNT1 TNNI3 MYBPC3
23 11.6 PRKAG3 PRKAG2 PRKAA2 PRKAA1
24 11.53 PRKAG3 PRKAG2 PRKAA2 MYH7
25
Show member pathways
11.49 TNNT2 TNNI3 PRKAG3 PRKAG2 PRKAA2 PRKAA1
26 11.45 TBX20 NKX2-5 BMP2
27 11.43 TNNT2 TNNI3 TBX20 NKX2-5
28 11.39 PRKAG3 PRKAG2 PRKAA2 PRKAA1
29
Show member pathways
11.19 PRKAG3 PRKAG2 PRKAA2 PRKAA1
30 11.01 PRKAG3 PRKAG2 PRKAA2 PRKAA1
31 10.67 PRKAG2 PRKAA2
32 10.6 NPPB NKX2-5 MYH7 BMP2

GO Terms for Wolff-Parkinson-White Syndrome

Cellular components related to Wolff-Parkinson-White Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sarcomere GO:0030017 9.56 TNNT2 TNNI3 MYH7 MYBPC3
2 myosin filament GO:0032982 9.37 MYH7 MYBPC3
3 nucleotide-activated protein kinase complex GO:0031588 9.33 PRKAG3 PRKAG2 PRKAA1
4 cardiac Troponin complex GO:1990584 9.32 TNNT2 TNNI3
5 troponin complex GO:0005861 9.13 TNNT2 TNNT1 TNNI3
6 cardiac myofibril GO:0097512 8.8 TNNT2 TNNI3 MYBPC3

Biological processes related to Wolff-Parkinson-White Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 10.08 PRKAG3 PRKAG2 PRKAA2 PRKAA1 BMP2
2 fatty acid metabolic process GO:0006631 9.91 PRKAG3 PRKAG2 PRKAA2 PRKAA1
3 cell cycle arrest GO:0007050 9.88 PRKAG3 PRKAG2 PRKAA2 PRKAA1
4 regulation of signal transduction by p53 class mediator GO:1901796 9.87 PRKAG3 PRKAG2 PRKAA2 PRKAA1
5 macroautophagy GO:0016236 9.83 PRKAG3 PRKAG2 PRKAA2 PRKAA1
6 vasculogenesis GO:0001570 9.79 TNNI3 TBX20 NKX2-5
7 inner ear development GO:0048839 9.79 KCNQ1 JAG1 BMP2
8 fatty acid biosynthetic process GO:0006633 9.78 PRKAG3 PRKAG2 PRKAA2 PRKAA1
9 regulation of macroautophagy GO:0016241 9.76 PRKAG3 PRKAG2 PRKAA2 PRKAA1
10 sterol biosynthetic process GO:0016126 9.73 PRKAG2 PRKAA2 PRKAA1
11 muscle contraction GO:0006936 9.72 TNNT2 TNNT1 TNNI3 TBX20 MYH7
12 cellular response to glucose starvation GO:0042149 9.71 PRKAG3 PRKAG2 PRKAA2 PRKAA1
13 striated muscle contraction GO:0006941 9.69 TNNI3 MYH7 CASQ2
14 embryonic heart tube development GO:0035050 9.68 TBX20 NKX2-5
15 endocardial cushion morphogenesis GO:0003203 9.68 TBX20 BMP2
16 cellular response to prostaglandin E stimulus GO:0071380 9.68 PRKAA2 PRKAA1
17 fatty acid homeostasis GO:0055089 9.67 PRKAA2 PRKAA1
18 cardiovascular system development GO:0072358 9.67 NKX2-5 KCNQ1
19 heart contraction GO:0060047 9.67 TNNI3 NKX2-5
20 regulation of muscle contraction GO:0006937 9.67 TNNT2 TNNT1 TNNI3
21 sarcomere organization GO:0045214 9.67 TNNT2 TNNT1 NKX2-5 CASQ2
22 cellular response to nutrient levels GO:0031669 9.66 PRKAA2 PRKAA1
23 adult heart development GO:0007512 9.66 NKX2-5 MYH7
24 cardiac right ventricle morphogenesis GO:0003215 9.65 TBX20 JAG1
25 atrial septum morphogenesis GO:0060413 9.65 TBX20 NKX2-5
26 negative regulation of ATPase activity GO:0032780 9.65 TNNT2 TNNI3
27 regulation of membrane repolarization GO:0060306 9.64 KCNQ1 CASQ2
28 transition between fast and slow fiber GO:0014883 9.64 TNNT1 MYH7
29 carnitine shuttle GO:0006853 9.63 PRKAG2 PRKAA2
30 regulation of fatty acid biosynthetic process GO:0042304 9.63 PRKAG2 PRKAA2
31 positive regulation of cellular protein localization GO:1903829 9.62 PRKAA2 PRKAA1
32 cardiac muscle tissue morphogenesis GO:0055008 9.61 TBX20 NKX2-5 BMP2
33 negative regulation of tubulin deacetylation GO:1904428 9.6 PRKAA2 PRKAA1
34 regulation of protein serine/threonine kinase activity GO:0071900 9.59 PRKAG3 PRKAG2
35 histone-serine phosphorylation GO:0035404 9.58 PRKAA2 PRKAA1
36 skeletal muscle contraction GO:0003009 9.56 TNNT2 TNNT1 TNNI3 MYH7
37 positive regulation of peptidyl-lysine acetylation GO:2000758 9.55 PRKAA2 PRKAA1
38 regulation of stress granule assembly GO:0062028 9.54 PRKAA2 PRKAA1
39 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.46 TNNT2 TNNI3 MYH7 MYBPC3
40 muscle filament sliding GO:0030049 9.35 TNNT2 TNNT1 TNNI3 MYH7 MYBPC3
41 cardiac muscle contraction GO:0060048 9.23 TNNT2 TNNT1 TNNI3 NKX2-5 MYH7 MYBPC3

Molecular functions related to Wolff-Parkinson-White Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 tropomyosin binding GO:0005523 9.49 TNNT2 TNNT1
2 protein kinase regulator activity GO:0019887 9.48 PRKAG3 PRKAG2
3 AMP binding GO:0016208 9.46 PRKAG3 PRKAG2
4 histone serine kinase activity GO:0035174 9.43 PRKAA2 PRKAA1
5 calcium-dependent ATPase activity GO:0030899 9.4 TNNT2 TNNT1
6 adenyl ribonucleotide binding GO:0032559 9.37 PRKAG3 PRKAG2
7 troponin T binding GO:0031014 9.32 TNNT1 TNNI3
8 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
9 [acetyl-CoA carboxylase] kinase activity GO:0050405 9.16 PRKAA2 PRKAA1
10 [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity GO:0047322 8.96 PRKAA2 PRKAA1
11 AMP-activated protein kinase activity GO:0004679 8.92 PRKAG3 PRKAG2 PRKAA2 PRKAA1

Sources for Wolff-Parkinson-White Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....